In our first paper on CD40 (3), we concluded that “this work in turn may help in devising strategies in vivo for the control of human diseases such as B-cell malignancies, immune-deficiencies, and certain autoimmune diseases.” Almost 30 years later, CD40 holds tremendous potential as a target for immunotherapeutics and vaccines. This evidence concerns the gene CD40 and autoimmune disease.